Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 1997

View Archived Issues

Annual Report: CellPro

Annual Report: Cangene

ZymoGenetics/Novo Nordisk isolate anticlotting agent

EPO activators/agonists described by J&J and Affymax

X-ray contrast agents from Schering AG

Human Genome Sciences describes MCP-4 polypeptide

Anti-factor Xa compounds disclosed by RPR

Zeneca describes ET antagonists

Retinoid series for cancer

BASF prepares dolastatin derivatives

TK inhibitors disclosed by RCT

HMR synthesizes potent AChE inhibitor

Combination Remune/triple anti-HIV therapy trial begins

Neuraminidase inhibitor holds promise for flu

Approval anticipated for TMR using Heart Laser

Biopharmaceutics/ABS form advisory team to advance filings for anticancer drug

Alza/Alkermes stock purchase and development agreements

Clinical development of HIV immunotherapeutic advances

Gliatech's ADCON-L nears FDA approval

Nymox drug candidate for AD to enter phase I

Inex and Schering-Plough complete research collaboration

Positive phase I safety profile for Immunex's new product candidate

Dermik launches new acne medication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...